Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study
- PMID: 33903963
- DOI: 10.1007/s00296-021-04862-y
Comparison of efficacy between anti-IL-6 receptor antibody and other biological disease-modifying antirheumatic drugs in the patients with rheumatoid arthritis who have knee joint involvement: the ANSWER cohort, retrospective study
Abstract
Objective: We aimed to investigate the efficacy of anti-IL-6 receptor antibody (aIL-6) and other biologic disease-modifying antirheumatic drugs (bDMARDs), such as TNF inhibitor and CTLA4-Ig in the treatment of rheumatoid arthritis (RA) in patients with knee joint involvement.
Methods: We retrospectively analyzed 1059 treatment courses of patients with RA who visited our hospitals and were treated with bDMARDs. We categorized them into two groups, with or without knee joint involvement. We investigated the clinical disease activity index (CDAI) at baseline and 12 weeks after the initiation of bDMARDs. We compared the improvement of the markers between aIL-6 and other bDMARDs.
Results: Treatment with aIL-6 significantly increased ΔCDAI (n = 91, 15.4 ± 1.1; mean ± SEM) in patients with knee joint involvement, compared to other bDMARDs (n = 232, 11.0 ± 0.7) at 12 weeks (P = 0.006). Following the multivariate analysis adjusted by the CDAI levels at baseline, age, gender, concomitant use of methotrexate, and the first use of bDMARDs, ΔCDAI levels were significantly higher in aIL-6, compared to other bDMARDs (P = 0.02). However, there was no significant difference in ΔCDAI improvement between aIL-6 (n = 162, 5.9 ± 0.6) and other bDMARDs (n = 573, 6.2 ± 0.4) in patients without swollen knee joints. ΔCDAI levels were equally increased in patients with shoulder and elbow joint involvement.
Conclusion: aIL-6 was more effective in the patients with RA and knee joint involvement, compared to other bDMARDs.
Keywords: Antirheumatic agents; Interleukin-6; Rheumatoid arthritis.
Similar articles
-
Tocilizumab in the treatment of adult rheumatoid arthritis.Immunotherapy. 2018 Mar 1;10(6):447-464. doi: 10.2217/imt-2017-0173. Epub 2018 Mar 2. Immunotherapy. 2018. PMID: 29495891 Review.
-
Anti-nuclear antibody development is associated with poor treatment response to biological disease-modifying anti-rheumatic drugs in patients with rheumatoid arthritis.Semin Arthritis Rheum. 2019 Oct;49(2):204-210. doi: 10.1016/j.semarthrit.2019.02.003. Epub 2019 Feb 10. Semin Arthritis Rheum. 2019. PMID: 30803720
-
Drug retention of 7 biologics and tofacitinib in biologics-naïve and biologics-switched patients with rheumatoid arthritis: the ANSWER cohort study.Arthritis Res Ther. 2020 Jun 15;22(1):142. doi: 10.1186/s13075-020-02232-w. Arthritis Res Ther. 2020. PMID: 32539813 Free PMC article.
-
Predictive factors and treatment outcomes associated with difficult-to-treat rheumatoid arthritis conditions: the ANSWER cohort study.Rheumatology (Oxford). 2024 Sep 1;63(9):2418-2426. doi: 10.1093/rheumatology/keae265. Rheumatology (Oxford). 2024. PMID: 38724245
-
Impact of biologic disease-modifying antirheumatic drugs on fracture risk in patients with rheumatoid arthritis: a systematic review and meta-analysis.Eur Rev Med Pharmacol Sci. 2021 May;25(9):3416-3424. doi: 10.26355/eurrev_202105_25821. Eur Rev Med Pharmacol Sci. 2021. PMID: 34002814
Cited by
-
Drug retention of biologics and Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.RMD Open. 2023 Aug;9(3):e003160. doi: 10.1136/rmdopen-2023-003160. RMD Open. 2023. PMID: 37597846 Free PMC article.
-
Study on the Predictive Value of Inflammatory Factors and Biomarkers in Synovial Fluid for Disease Progression in Knee Osteoarthritis Patients.J Musculoskelet Neuronal Interact. 2025 Jun 1;25(2):186-191. doi: 10.22540/JMNI-25-186. J Musculoskelet Neuronal Interact. 2025. PMID: 40452194 Free PMC article.
-
Effects of IL-6, JAK, TNF inhibitors, and CTLA4-Ig on knee symptoms in patients with rheumatoid arthritis.Sci Rep. 2024 Jul 2;14(1):15226. doi: 10.1038/s41598-024-66064-3. Sci Rep. 2024. PMID: 38956271 Free PMC article.
-
Factors affecting drug retention of Janus kinase inhibitors in patients with rheumatoid arthritis: the ANSWER cohort study.Sci Rep. 2022 Jan 7;12(1):134. doi: 10.1038/s41598-021-04075-0. Sci Rep. 2022. PMID: 34997059 Free PMC article.
-
Differential efficacy of TNF inhibitors with or without the immunoglobulin fragment crystallizable (Fc) portion in rheumatoid arthritis: the ANSWER cohort study.Rheumatol Int. 2022 Jul;42(7):1227-1234. doi: 10.1007/s00296-021-05086-w. Epub 2022 Mar 10. Rheumatol Int. 2022. PMID: 35266034
References
-
- Scott DL, Wolfe F, Huizinga TW (2010) Rheumatoid arthritis. Lancet 376(9746):1094–1108. https://doi.org/10.1016/s0140-6736(10)60826-4 - DOI - PubMed
-
- Maeda Y, Kurakawa T, Umemoto E, Motooka D, Ito Y, Gotoh K et al (2016) Dysbiosis contributes to arthritis development via activation of autoreactive T cells in the intestine. Arthritis Rheumatol 68(11):2646–2661. https://doi.org/10.1002/art.39783 - DOI - PubMed
-
- Kishikawa T, Maeda Y, Nii T, Motooka D, Matsumoto Y, Matsushita M et al (2020) Metagenome-wide association study of gut microbiome revealed novel aetiology of rheumatoid arthritis in the Japanese population. Ann Rheum Dis 79(1):103–111. https://doi.org/10.1136/annrheumdis-2019-215743 - DOI - PubMed
-
- Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K et al (2014) Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature 506(7488):376–381. https://doi.org/10.1038/nature12873 - DOI - PubMed - PMC
-
- Hashimoto M, Yamazaki T, Hamaguchi M, Morimoto T, Yamori M, Asai K et al (2015) Periodontitis and Porphyromonas gingivalis in preclinical stage of arthritis patients. PLoS ONE 10(4):e0122121. https://doi.org/10.1371/journal.pone.0122121 - DOI - PubMed - PMC
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical